| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
American Journal of Epidemiology Vol. 102, No. 4: 341-349
Copyright © 1975 by The Johns Hopkins University School of Hygiene and Public Health
other |
MEASLES MORTALITY: A RETROSPECTIVE LOOK AT THE VACCINE ERA1
2Currently, Department of Pediatrics, University of Colorado Medical Center Denver, CO.
Reprint requests to Bureau of Epidemiology, Center for Disease Control, Atlanta, GA 30333.
Barkin, R. M. (Bureau of Epidemiology, CDC, Atlanta, GA 30333). Measles mortality: A retrospective look at the vaccine era.Am J Epidemiol102:341–349, 1975.
Measles mortality provides an indicator in defining the population at greatest risk of experiencing serious complications from measles as well as serving as a parameter in assessing the impact of immunization programs. Efforts to vaccinate susceptible children have helped to reduce measles morbidity and mortality in the United States. Mortality rates were highest in children 6–11 months of age. Higher mortality rates were noted in places with less than 10,000 people and in counties having a large percentage of the population with incomes below poverty level. Vaccine should be accessible to all populations, but intensive efforts need to be directed toward groups at high risk of dying from measles who are suffering from a myriad of other health, social, and economic problems.
Measles; mortality; vaccination
1From the Field Services Branch, Bureau of Epidemiology, and Immunization Branch, Bureau of State Services, Center for Disease Control, Atlanta, GA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. A. Poland, R. M. Jacobson, R. A. Vierkant, S. A. Colbourne, A. M. Thampy, V. S. Pankratz, and S. J. Jacobsen Effect of Differing Immunization Policies on Circulating Measles Antibody Levels in US and Canadian Children Mayo Clin. Proc., May 1, 2002; 77(5): 446 - 452. [Abstract] [PDF]
|
|
|
|
 |
|
 R. L. Davis, E. M. MD, S. Black, H. Shinefield, B. Givens, J. Schwalbe, P. Ray, R. S. Thompson, R. Chen, and the Vaccine Safety Datalink Team MMR2 Immunization at 4 to 5 Years and 10 to 12 Years of Age: A Comparison of Adverse Clinical Events After Immunization in the Vaccine Safety Datalink Project Pediatrics, November 1, 1997; 100(5): 767 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Poland, R. M. Jacobson, A. M. Thampy, S. A. Colbourne, P. C. Wollan, J. J. Lipsky, and S. J. Jacobsen Measles Reimmunization in Children Seronegative After Initial Immunization JAMA, April 9, 1997; 277(14): 1156 - 1158. [Abstract] [PDF]
|
|
|
|
|
|
W. A. Orenstein, A. Bloch, R. H. Bernier, K. Bart, and A. R. Hinman Measles Vaccination in Infants-Reply JAMA, March 5, 1982; 247(9): 1273 - 1274. [Abstract] [PDF]
|
|
|
|
|
|
R. A. Goodman, K. G. Manton, T. F. Nolan Jr, D. J. Bregman, and A. R. Hinman Mortality Data Analysis Using a Multiple-Cause Approach JAMA, February 12, 1982; 247(6): 793 - 796. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Morishima, M. Miyazu, T. Ozaki, S. Isomura, and S. Suzuki Local Immunity in Mumps Meningitis Arch Pediatr Adolesc Med, November 1, 1980; 134(11): 1060 - 1064. [Abstract] [PDF]
|
|
|
|
 |
|
 K. H. RAND and P. D. REUMAN Measles: Ready for Eradication? Ann Intern Med, June 1, 1979; 90(6): 978 - 980. [Abstract] [PDF]
|
|